Maravai LifeSciences (MRVI) supplies a key component of the coronavirus vaccine produced by Pfizer (PFE) and BioNTech (BNTX). The vaccine should provide a sharp increase in revenue. The company also has a diversified product portfolio.
For those following the Good Way, the Buy Now rating is ‘YES.’
For those following the Best Way the buy zone is $23 to $26.76. MRVI is trading at $26.31 as of this writing in the premarket.
The stop zone is $21.38 to $22.33. The first target zone is $29 to $32. The second target zone is $35 to $38. The maximum quantity is 30% of full core position size.
So far this company has not caught the momo crowd’s attention. If it catches the momo crowd’s attention, it has the potential to move up rapidly. On the other hand, if this stock does not get pumped by the pumpers, it is likely to be a slow grind up until earnings are released.
Caution: this is a recent IPO. As such, there is not a lot of historical data to analyze. From a technical perspective, the stock has traded as high as $32.46 and a pullback provides an opportunity.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.